Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07134088 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
A Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT07134088: Recruiting Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, sponsored by Amgen.
NCT07134088 is a Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Amgen. The registered enrollment target is 104 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07134088, a Phase 1 study of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Conditions Studied
Interventions
- DRUG Blinatumomab
Study Locations (2)
Tennessee
- St Jude Childrens Research Hospital - Memphis
Kanagawa
- Kanagawa Childrens Medical Center - Yokohami-shi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2030-06-18 |
| Phase | Phase 1 |
What NCT07134088 shows while recruiting
NCT07134088 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% higher).
The record links to 2 conditions, with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Blinatumomab is the first listed.
NCT07134088 reports a single indexed study location in Tennessee, Kanagawa.
Frequently Asked Questions
What is clinical trial NCT07134088 about?
NCT07134088 is a clinical study titled "A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia". The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
What is the current status of trial NCT07134088?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2025-12-08. Estimated completion is 2030-06-18.
What conditions does trial NCT07134088 study?
This clinical trial studies the following conditions: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT07134088?
The interventions under investigation include: Blinatumomab (DRUG).
Who is sponsoring clinical trial NCT07134088?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07134088 being conducted?
This trial has 2 study locations across Tennessee, Kanagawa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07134088's enrollment target sits among peer trials
104 537th of 2000 higher than 1,460 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI